Tirzepatide

Dual GIP/GLP-1 agonist. Mounjaro/Zepbound active compound.

Product Information

• Compound: Tirzepatide
• Category: Metabolic research
• Form: Lyophilized powder, single-use vial

Tirzepatide: Mechanism & Published Research

Tirzepatide is a synthetic dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed as a once-weekly subcutaneous peptide, it has been the subject of extensive published clinical research under the brand study names SURPASS and SURMOUNT, positioning it as one of the most-studied dual incretin agonists in the literature.

In the published pharmacology literature, researchers have described tirzepatide's GIPR agonism as a key differentiator from GLP-1 mono-agonists. The GIPR component is thought to enhance insulin secretion in a glucose-dependent manner, suppress glucagon, and modulate adiponectin levels in adipose tissue. Combined with GLP-1R agonism — which suppresses appetite via hypothalamic signaling and slows gastric emptying — the dual mechanism has attracted significant research interest in metabolic and body composition studies.

Tirzepatide shares structural features with native GIP, including an N-terminal Tyr-Aib dipeptide modification that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, and a C-18 fatty diacid conjugate via a linker that promotes albumin binding. The published half-life in human pharmacokinetic studies is approximately five days, enabling the once-weekly dosing protocols studied in clinical trials.

Published tirzepatide research is compared in our tirzepatide vs retatrutide research comparison. Researchers have also examined its effects on non-alcoholic fatty liver disease biomarkers, cardiac function parameters, and sleep apnea endpoints in separate study arms, reflecting the breadth of metabolic research interest in this compound class.

Canada Peptide Supply offers tirzepatide as lyophilized powder in vials from 5 mg to 60 mg. Tirzepatide sold here is not approved by Health Canada for human use and is sold strictly for in-vitro laboratory research.

Research use only: this information is provided for scientific reference. Canada Peptide Supply does not provide medical advice. Tirzepatide is not approved by Health Canada for human consumption, diagnosis, treatment, or prevention of disease.

Batch documentation

Before ordering, contact us with the product name and selected size to ask which batch documentation is available. For an existing order, include the batch number on the label. Match any certificate to the exact batch and review the methods and results reported; a purity result alone does not establish sterility or suitability for human use. See our COA policy.

Shipping within Canada

Orders ship within Canada. Standard shipping is $24.99 CAD and express shipping is $49.99 CAD. Free standard shipping applies to a merchandise subtotal of $250 CAD or more; express shipping is not included. Review shipping, dispatch and returns before ordering. Transit estimates begin after dispatch.

Intended Use

This product is sold strictly for laboratory research, in-vitro testing, and analytical reference. It is not approved by Health Canada for human consumption, diagnosis, treatment, or prevention of disease. Buyer must be 21 years of age or older. By purchasing, you agree to our Terms of Sale.

Frequently asked about Tirzepatide

Compare Tirzepatide options

Select an option in the product selector to view its details and order. Prices and availability may change.

Browse the research catalog or ask a product question.